期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

FOXC1在复发性乳腺浸润性导管癌中的表达及其意义 被引量：2

FOXC1 expression in relapsing invasive ductal carcinoma
下载PDF
导出
摘要 目的:探讨FOXC1蛋白表达与复发性乳腺浸润性导管癌的临床病理特征间相关性。方法:采用免疫组化S-P法检测42例复发性乳腺癌石蜡组织中FOXC1蛋白的表达。结果:FOXC1蛋白在21例(50%)乳腺浸润性导管癌中表达,定位于胞核。FOXC1阳性表达与乳腺浸润性导管癌组织学分级相关(P<0.05),与复发性乳腺癌患者的耐药情况及患者辅助化疗后的PFS相关(P<0.05),与乳腺癌患者的年龄,淋巴结转移的数量以及原发肿块的大小无明显的统计学相关性(P>0.05)。结论:FOXC1蛋白参与了复发性乳腺癌的耐药机制,但其可能与乳腺癌原发肿瘤的发生发展及淋巴结转移无关。 Objective：To investigate potential correlations between FOXC1 expression and clinicopathologic features of relapsing invasive ductal carcinoma.Methods：FOXC1 protein expression in 42 cases of relapsing invasive ductal carcinoma were investigated with immunohistochemistry.Results：FOXC1 protein expression was observed in invasive ductal carcinoma tissues.Positive FOXC1 expression was revealed in 21（50.0 %）invasive ductal carcinoma.Significant correlation in retrospective study was observed between FOXC1 protein expression and histological grades（P0.05）as well as drug resistance and PFS after adjuvant chemotherapy（P0.05）.No significant association was shown between FOXC1 protein expression in invasive ductal carcinoma and clinicopathological factors including pathological type,age,primary tumor size,TNBC and non-TNBC,lymph node metastasis,etc（P0.05）.Conclusion：FOXC1 may play a role in malignant degree and drug resistance to relapsing invasive ductal carcinoma.
作者 贾海全 赵国强
机构地区 郑州大学基础医学院病理学与病理生理学教研室
出处 《重庆医科大学学报》 CAS CSCD 北大核心 2011年第11期1372-1374,共3页 Journal of Chongqing Medical University
关键词 复发性乳腺癌 转录因子FOXC1 免疫组化 relapsing invasive ductal carcinoma transcriptional factor FOXC1 immunohistochemistry
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献13

  • 1Bergamaschi A,Hjortland G O,Tfiulzi T,et al.Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models[J].Mol Oncol, 2009,3 ( 5-6 ) : 469-482.
  • 2Perou C M, Sφrlie T,Eisen M B, et al.Molecular portraits of human breast tumours[J].Nature, 2000,406(6797) : 747-752.
  • 3Mears A J,Jordan T,Mirzayans F,et al.Mutations of the forkhead/ winged-helix gene,FKHL7,in patients with Axenfeld-Rieger anomaly [J].Am J Hum Genet, 1998,63(5) : 1316-1328.
  • 4Gould D B,Mears A J,Pearce W G,et al.Autosomal dominant Axenfeld-Rieger anomaly maps to 6p25[J].Am J Hum Genet, 1997,61 (3) : 765-768.
  • 5Kops G J,de Ruiter N D, De Vries-Smits A M,et al.Direct control of the Forkhead transcription factor AFX by protein kinase B[J].Nature, 1999,398(6728) :630-634.
  • 6Bergamaschi A,Kim Y H,Wang P,et al.Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer[J].Genes Chromosomes Cancer,2006,45(11) : 1033-1040.
  • 7Ra P S,Wang J,Qu Y,et al.FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer[J]. Cancer Res, 2010,70(10) : 3870-3876.
  • 8Chean M C,Voduc D,Bajdik C,et al.Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype[J].Clin Cancer Res,2008,14(5) : 1368-1376.
  • 9Ame J B,Begin L R,Stefansson I,et al,Expression of epidermal growth factor receptor in relation to BRCA1 status,basal-like markers and prognosis in breast cancer[J].Joumal of Clinical Pathology, 2009,62 (2) : 139-146.
  • 10Yagata H,Kajiura Y,Yamauchi H.Current strategy for triple-negative breast cancer:appropriate combination of surgery,radiation,and chemotherapy[J].Breast Cancer, 2011,18 (3) : 165-173.

同被引文献38

  • 1Stern DF, Heffernan PA, Wenberg RA. p185, a product of the neu proto- oneogene,is a reeeptorlike protein associated with tyrosine kinase activity[J]. Mol Cell Biol, 1986,6 (5) : 1729-1740.
  • 2Essapen S,Thomas H, Green M,et al. The expression and prognostic sig- nificance of HER-2 in eolorectal cancer and its relationship with elinieo- pathological parameters [J]. Int J Oncol, 2004,24 (2) : 241-248.
  • 3Half E, Broaddus R, Danenberg KD, et al. HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tu- mors [J]. Int J Cancer,2004,108(4) :540-548.
  • 4Pohl M, Strieker I, Schoeneck A, et al. Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo[J]. J Cancer Res Clin Onco1,2009,135 (10) : 1377-1386.
  • 5Vogel CL, Cobleigh MA,Tripathy D, et al. Efficacy and safety of trastuzu- mab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer[J]. Clin Oncol, 2002,20 (3) : 719-726.
  • 6Riemer AB, Klinger M,Wagner S, et al. Generation of Peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/ neu[J]. J Immunol, 2004,173 ( I ) : 394-401.
  • 7Marx AH, Burandt EC,Chosehzick M,et al. Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers[J]. Hum Pathol, 2010,41 ( 11 ) : 1577-1585.
  • 8Sabatier R,Finetti P,Cervera N ,et al. A gene expression signature identi- fies two prognostic subgroups of basal basal cancer[J]. Brest Cancer Res Treat ,2011,126(2) :407-420.
  • 9Kops G J, de Ruiter ND,de Vries-Smits AM, et al. Direct control of the Forkhead transcription factor AFX by protein kinase B[J]. Nature, 1999, 398 (6728) : 630-634.
  • 10Bergamaschi A,Kim YH,Wang P,et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological fea- tures and gene-expression subtypes of breast cancer[J]. Genes chromo- somes cancer, 2006,45 (11 ) : 1033-1040.

引证文献2

二级引证文献3

重庆医科大学学报
2011年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部